vs
自由媒体集团（OLP）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是自由媒体集团的1.2倍（$30.3M vs $24.7M），自由媒体集团净利率更高（9.7% vs -221.3%，领先231.1%），REGENXBIO Inc.同比增速更快（43.0% vs 3.7%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 4.4%）
自由媒体集团是1991年由约翰·C·马龙创立的美国大众传媒企业，集团目前按不同追踪股票划分业务板块，持有一级方程式集团和Live Nation娱乐的股权，截至2025年，集团共拥有一级方程式、MotoGP以及世界超级摩托车锦标赛三大全球赛车运动业务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
OLP vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.2倍
$24.7M
营收增速更快
RGNX
高出39.3%
3.7%
净利率更高
OLP
高出231.1%
-221.3%
两年增速更快
RGNX
近两年复合增速
4.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $24.7M | $30.3M |
| 净利润 | $2.4M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 28.6% | -190.0% |
| 净利率 | 9.7% | -221.3% |
| 营收同比 | 3.7% | 43.0% |
| 净利润同比 | -77.1% | -31.2% |
| 每股收益（稀释后） | $0.10 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OLPRGNX
| Q4 25 | $24.7M | $30.3M | ||
| Q3 25 | $23.8M | $29.7M | ||
| Q2 25 | $24.5M | $21.4M | ||
| Q1 25 | $24.2M | $89.0M | ||
| Q4 24 | $23.9M | $21.2M | ||
| Q3 24 | $22.2M | $24.2M | ||
| Q2 24 | $21.8M | $22.3M | ||
| Q1 24 | $22.7M | $15.6M |
净利润OLPRGNX
| Q4 25 | $2.4M | $-67.1M | ||
| Q3 25 | $10.5M | $-61.9M | ||
| Q2 25 | $8.4M | $-70.9M | ||
| Q1 25 | $4.2M | $6.1M | ||
| Q4 24 | $10.6M | $-51.2M | ||
| Q3 24 | $5.2M | $-59.6M | ||
| Q2 24 | $9.6M | $-53.0M | ||
| Q1 24 | $5.2M | $-63.3M |
毛利率OLPRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率OLPRGNX
| Q4 25 | 28.6% | -190.0% | ||
| Q3 25 | 66.7% | -176.3% | ||
| Q2 25 | 62.6% | -296.3% | ||
| Q1 25 | 39.8% | 13.6% | ||
| Q4 24 | 65.0% | -242.1% | ||
| Q3 24 | 45.0% | -256.6% | ||
| Q2 24 | 66.0% | -251.3% | ||
| Q1 24 | 44.1% | -408.8% |
净利率OLPRGNX
| Q4 25 | 9.7% | -221.3% | ||
| Q3 25 | 44.1% | -208.3% | ||
| Q2 25 | 34.3% | -331.8% | ||
| Q1 25 | 17.2% | 6.8% | ||
| Q4 24 | 44.1% | -241.3% | ||
| Q3 24 | 23.3% | -246.3% | ||
| Q2 24 | 43.8% | -237.7% | ||
| Q1 24 | 22.7% | -405.4% |
每股收益（稀释后）OLPRGNX
| Q4 25 | $0.10 | $-1.30 | ||
| Q3 25 | $0.48 | $-1.20 | ||
| Q2 25 | $0.39 | $-1.38 | ||
| Q1 25 | $0.18 | $0.12 | ||
| Q4 24 | $0.49 | $-0.99 | ||
| Q3 24 | $0.23 | $-1.17 | ||
| Q2 24 | $0.45 | $-1.05 | ||
| Q1 24 | $0.23 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $14.4M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $299.6M | $102.7M |
| 总资产 | $857.6M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OLPRGNX
| Q4 25 | $14.4M | $230.1M | ||
| Q3 25 | $18.8M | $274.2M | ||
| Q2 25 | $19.0M | $323.3M | ||
| Q1 25 | $8.2M | $267.9M | ||
| Q4 24 | $42.3M | $234.7M | ||
| Q3 24 | $25.7M | $255.5M | ||
| Q2 24 | $35.0M | $290.4M | ||
| Q1 24 | $27.4M | $338.7M |
股东权益OLPRGNX
| Q4 25 | $299.6M | $102.7M | ||
| Q3 25 | $305.6M | $161.5M | ||
| Q2 25 | $303.4M | $213.7M | ||
| Q1 25 | $303.2M | $274.2M | ||
| Q4 24 | $307.4M | $259.7M | ||
| Q3 24 | $304.2M | $301.4M | ||
| Q2 24 | $307.3M | $348.3M | ||
| Q1 24 | $304.8M | $390.7M |
总资产OLPRGNX
| Q4 25 | $857.6M | $453.0M | ||
| Q3 25 | $802.3M | $525.2M | ||
| Q2 25 | $795.6M | $581.0M | ||
| Q1 25 | $811.7M | $490.9M | ||
| Q4 24 | $767.0M | $466.0M | ||
| Q3 24 | $768.8M | $519.1M | ||
| Q2 24 | $759.2M | $569.4M | ||
| Q1 24 | $755.7M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $37.5M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | 15.54× | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流OLPRGNX
| Q4 25 | $37.5M | $-52.3M | ||
| Q3 25 | $10.9M | $-56.0M | ||
| Q2 25 | $11.2M | $-49.3M | ||
| Q1 25 | $11.0M | $33.6M | ||
| Q4 24 | $39.1M | $-31.6M | ||
| Q3 24 | $10.0M | $-40.5M | ||
| Q2 24 | $8.6M | $-45.5M | ||
| Q1 24 | $8.9M | $-55.5M |
自由现金流OLPRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率OLPRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度OLPRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率OLPRGNX
| Q4 25 | 15.54× | — | ||
| Q3 25 | 1.04× | — | ||
| Q2 25 | 1.33× | — | ||
| Q1 25 | 2.65× | 5.53× | ||
| Q4 24 | 3.70× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.90× | — | ||
| Q1 24 | 1.73× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OLP
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
